One of the original synthetic growth hormone releasing peptides, with potent GH secretagogue activity and notable appetite-stimulating effects through ghrelin receptor engagement.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →GHRP-6 — Growth Hormone Releasing Peptide 6 — is a synthetic hexapeptide that was one of the first compounds ever developed specifically to stimulate endogenous growth hormone secretion. It was created in the early 1980s by Cyril Bowers and colleagues at Tulane University as part of a program to find small, orally active analogs of enkephalin (an endogenous opioid peptide) that could stimulate GH release. The “6” in its name refers to the six amino acids in the sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. The inclusion of D-amino acids (D-tryptophan and D-phenylalanine) is intentional — these non-natural amino acid configurations make the peptide resistant to proteolytic degradation by enzymes that recognize only L-amino acids, improving stability compared to purely natural peptide sequences.
GHRP-6 is classified as a growth hormone secretagogue (GHS) — a compound that stimulates GH secretion through a mechanism other than growth hormone-releasing hormone (GHRH). For years after its development, GHRP-6 was a research tool without a clear receptor identity, until the ghrelin receptor (now formally named GHS-R1a) was deorphanized in 1996. This discovery revealed that GHRP-6, along with other synthetic GHSs, was activating the same receptor as ghrelin — an endogenous peptide hormone produced by the stomach that regulates hunger, GH secretion, and energy metabolism. GHRP-6 is thus best understood as a synthetic ghrelin receptor agonist, engineered to activate the ghrelin receptor more potently or consistently than ghrelin itself for research and clinical investigation purposes.
What distinguishes GHRP-6 from later-generation GH secretagogues is a dual characteristic that is both its main advantage and its most important limitation in certain contexts: it produces robust GH release accompanied by a pronounced appetite-stimulating effect. The appetite drive with GHRP-6 is among the strongest of any GHS compound, more intense than what is typically seen with GHRP-2 or ipamorelin. This hunger stimulation is not a side effect in the incidental sense — it is a direct, expected pharmacological consequence of GHS-R1a activation in the hypothalamic circuits that regulate food intake. Depending on the research goal, this property can be either useful (in wasting diseases, cachexia, or mass gain protocols) or problematic (in contexts where body composition optimization without appetite stimulation is desired).
GHRP-6 was instrumental in establishing the scientific framework for the entire GHS class of compounds, and much of what we understand about GH secretagogue pharmacology — receptor identity, downstream signaling, synergy with GHRH, and the relationship between ghrelin-axis activation and metabolic phenotype — was worked out using GHRP-6 as a primary research tool. It remains in active use in research contexts and is compared directly to newer GHRPs and non-peptide GHS compounds. Compare GHRP-6 to GHRP-2, ipamorelin, and other GHS compounds in the Peptide Database.
GHRP-6’s primary mechanism of action is agonism of GHS-R1a (Growth Hormone Secretagogue Receptor type 1a), a G protein-coupled receptor expressed predominantly in the pituitary somatotroph cells and in the hypothalamus, but also in the heart, adrenal gland, pancreas, and other peripheral tissues. Unlike many GPCRs primarily coupled to Gs, GHS-R1a signals predominantly through Gq/11, which activates phospholipase C (PLC). PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol trisphosphate (IP3) and diacylglycerol (DAG).
IP3 binds its receptor on the endoplasmic reticulum and triggers rapid release of calcium from intracellular stores. The resulting cytoplasmic calcium spike is the direct trigger for GH vesicle exocytosis from somatotroph cells — calcium promotes fusion of GH-containing secretory vesicles with the plasma membrane, releasing GH into the portal circulation. DAG simultaneously activates protein kinase C (PKC), which provides a secondary amplification signal for GH secretion and also contributes to downstream gene regulation. This calcium-dependent exocytosis mechanism is distinct from the cAMP-mediated pathway used by GHRH, which is why GHRP-6 and GHRH are synergistic rather than redundant when combined — they drive GH release through complementary cellular mechanisms that summate at the level of secretory vesicle fusion.
GHRP-6 stimulates GH release through two distinct anatomical loci: directly at the pituitary somatotroph and indirectly through the hypothalamus. At the pituitary level, GHRP-6 acts directly on GHS-R1a expressing somatotroph cells to trigger calcium-dependent GH vesicle exocytosis as described above. At the hypothalamic level, GHS-R1a is expressed on neurons in the arcuate nucleus and other GH-regulatory regions. GHRP-6 binding to these hypothalamic receptors stimulates additional GH-releasing hormone (GHRH) release from the hypothalamus, which then travels through the portal circulation to the pituitary and further amplifies GH secretion through the cAMP/PKA pathway. This two-site mechanism explains why the GH response to GHRPs typically exceeds what would be predicted from pituitary stimulation alone.
Additionally, GHRP-6 suppresses somatostatin (SST) tone — the primary inhibitory brake on GH secretion — in the hypothalamus. Somatostatin neurons in the periventricular nucleus tonically inhibit both GHRH neurons and pituitary somatotrophs. GHRP-6-induced reduction in somatostatin tone creates a permissive environment for maximal GH release. This three-pronged effect (direct pituitary, hypothalamic GHRH amplification, and somatostatin suppression) is responsible for the robust GH pulses seen with GHRP-6 administration and for the particularly dramatic synergy when GHRP-6 is combined with exogenous GHRH.
The appetite stimulation produced by GHRP-6 — the property that most distinguishes it from newer GHRPs — involves GHS-R1a activation in both peripheral and central orexigenic circuits. The ghrelin receptor (GHS-R1a) evolved as the receptor for stomach-derived ghrelin, a hunger hormone released pre-prandially that signals to the brain via vagal afferents and direct hypothalamic action to drive food-seeking behavior. GHRP-6, as a ghrelin receptor agonist, activates the same circuits.
In the hypothalamus, GHRP-6 activates neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the arcuate nucleus — the primary orexigenic neurons that drive hunger by stimulating feeding and inhibiting satiety signals. These neurons project to the paraventricular nucleus and lateral hypothalamus to increase meal initiation and caloric intake. Simultaneously, GHRP-6 activates vagal gastric motility circuits — the same pathways by which ghrelin promotes gastric emptying and hunger contractions. This peripheral component of appetite stimulation (increased gastric motility, faster gastric emptying) contributes to the hunger sensation that users of GHRP-6 typically experience within 15–30 minutes of administration. Compared to GHRP-2 and especially ipamorelin, which have progressively less hypothalamic appetite activation, GHRP-6 has the strongest orexigenic signal of the major GHRPs.
Much of the early GHRP-6 research was not therapeutic in intent but rather diagnostic and mechanistic — researchers needed to understand how GH secretion could be pharmacologically stimulated and what the ceiling of GH release was under various conditions. GHRP-6 became a research standard for these purposes. Studies in healthy volunteers, GH-deficient adults, children with idiopathic short stature, and elderly subjects all used GHRP-6 as a stimulation test to characterize the GH secretory reserve. The classic finding across these studies was that GHRP-6 produced a robust, reproducible GH peak approximately 30–45 minutes after administration, with the magnitude of the peak dependent on somatostatin tone (which varies with nutritional state, sleep, and stress).
In GH-deficient patients, GHRP-6 testing revealed preserved pituitary somatotroph capacity even when endogenous GH secretion was diminished due to hypothalamic deficiency — an important diagnostic distinction. In elderly subjects, where GH secretion is blunted relative to young adults, GHRP-6 produced GH peaks that were smaller than in young adults but still significantly above baseline, demonstrating that pituitary responsiveness is partially preserved with aging even as the hypothalamic GH pulse generator slows down. This axis-characterization research using GHRP-6 was foundational for understanding GH physiology across the lifespan.
The orexigenic properties of GHRP-6 have been specifically studied in the context of conditions where appetite loss and muscle wasting are clinical problems. Cachexia — the muscle-wasting syndrome associated with cancer, AIDS, chronic heart failure, COPD, and other serious illnesses — represents a setting where both appetite stimulation and anabolic GH/IGF-1 signaling could theoretically provide benefit. Research in cachectic animal models has shown that GHRP-6 increases food intake, reduces muscle protein breakdown, and improves lean body mass. Clinical studies in conditions associated with appetite loss have confirmed that GHS-R1a agonists (using both GHRP-6 and ghrelin itself as tools) can meaningfully increase caloric intake and attenuate lean tissue loss.
In healthy research subjects without cachexia who used GHRP-6 in the context of body composition studies, the combination of GH-mediated lipolysis and GHS-R1a-mediated appetite increase created a nuanced effect: total body mass tended to increase (due to greater food intake), but fat mass changes were variable depending on whether caloric intake was controlled or ad libitum. When caloric intake was carefully managed, GH-mediated lipolysis predominated, improving fat-to-lean ratios despite increased appetite signaling. This interaction between appetite stimulation and GH lipolysis is central to understanding GHRP-6 in body composition research contexts.
A well-documented characteristic of GHRP-6 — and one that distinguishes it from newer, more selective GHRPs — is its stimulation of both cortisol and prolactin in addition to GH. GHRP-6 activates GHS-R1a-expressing cells in the adrenal cortex and increases ACTH from the pituitary, leading to measurable increases in serum cortisol within 30–60 minutes of administration. Prolactin is similarly elevated through GHS-R1a effects on pituitary lactotroph cells. These are not artifacts of supraphysiological dosing — they occur at doses that produce meaningful GH release.
The cortisol elevation with GHRP-6 is typically modest and transient, not reaching levels associated with clinical hypercortisolism, but it is pharmacologically meaningful and has driven interest in alternatives with less corticotropic activity. GHRP-2 also elevates cortisol and prolactin (and by some measures more so than GHRP-6), while ipamorelin was specifically engineered to minimize these effects. The clinical significance of the cortisol response depends heavily on context — in elderly or stressed individuals where HPA axis activation is undesirable, even modest cortisol increases have potential metabolic and immune implications. In healthy adults engaged in short-duration research protocols, the transient cortisol response is generally considered tolerable but worth monitoring.
Perhaps surprisingly for a GH secretagogue, GHRP-6 has demonstrated direct cardioprotective effects that appear to be independent of its GH-stimulating activity. Research teams in Cuba, led by Berlanga and Valdes, published extensive work showing that GHRP-6 reduces infarct size, preserves left ventricular function, and reduces myocardial apoptosis in rodent models of ischemia-reperfusion injury. Critically, these effects were demonstrated in hypophysectomized animals (animals without a pituitary gland, making GH secretion impossible) and were not blocked by a GH receptor antagonist — confirming a GH-independent mechanism.
The cardioprotective mechanism appears to involve direct GHS-R1a signaling in cardiomyocytes, where the IP3/calcium pathway activates cardioprotective signaling including PI3K/AKT and ERK1/2 survival pathways. GHRP-6 also significantly reduced cardiac inflammatory infiltration and reduced MMP activity in the infarcted myocardium, suggesting an anti-inflammatory component to its cardiac effects. This direct cardioprotective profile of GHRP-6 (and related GHRPs) has generated pharmaceutical interest in the concept of non-GH-mediated applications for GHS compounds.
The historical context of GHRP-6 is illuminated by comparison to the GHRPs that came after it. Hexarelin was developed as a more potent GHS-R1a agonist and does produce higher GH peaks than GHRP-6, but with even more pronounced cortisol and prolactin elevation and rapid desensitization with repeated use. GHRP-2 (covered separately) produces the strongest GH output of commonly used GHRPs while maintaining moderate (not maximal) appetite stimulation and a somewhat different cortisol profile. Ipamorelin was the refinement that specifically minimized cortisol and prolactin stimulation at the cost of somewhat lower GH output, making it the preferred choice when hormonal “cleanliness” is prioritized.
GHRP-6’s place in this lineage is as the foundational compound — well-studied, reliable, with the most research history behind it. Its combination of meaningful GH release, strong appetite stimulation, and moderate cortisol/prolactin effects means it is best suited for research contexts where the orexigenic component is a feature rather than a limitation. For most body composition optimization contexts in healthy individuals, GHRP-2 or ipamorelin have largely superseded GHRP-6 due to their more favorable side effect profiles. Browse the full GHS comparison in the Peptide Database.
GHRP-6 is administered subcutaneously or intramuscularly in research contexts. The most commonly studied dose range is 100–300 micrograms per administration, with most research protocols using 100 micrograms as a standard “pulse” dose. Below 100 micrograms, GH stimulation is measurable but may be submaximal; above 200–300 micrograms, the incremental GH response flattens due to GHS-R1a saturation, but the appetite-stimulating and cortisol-elevating effects continue to increase. This means higher doses of GHRP-6 don’t necessarily produce proportionally more GH but do produce progressively more of the undesirable side effects — supporting a dose range of 100–200 micrograms as the practical research window. The Peptide Dosage Calculators can assist with reconstitution and volume calculations.
Like other GH secretagogues, GHRP-6 is most effective when administered during periods of low somatostatin tone — which in practice means in a fasted state, away from meals. Carbohydrates and insulin (the latter suppressing GH through IGFBP elevation and somatostatin activation) significantly blunt the GH response. Research protocols typically time GHRP-6 injections at least 2 hours after a carbohydrate-containing meal and recommend avoiding food for 30–60 minutes after injection to maximize the GH pulse. Administration before sleep is common to take advantage of the natural nighttime GH secretory environment. Dosing frequency in research protocols ranges from once to three times daily; the most common approach is twice daily (morning fasted and before sleep).
The most potent GH stimulation from GHRP-6 is achieved when it is combined with a GHRH analog (such as CJC-1295, Mod-GRF 1-29, or sermorelin). The synergy between GHS-R1a agonism (GHRP-6’s mechanism) and GHRH receptor agonism is well-documented and produces GH peaks several times larger than either compound alone. The physiological basis for this synergy is that GHRH primes somatotroph cells through cAMP/PKA and increases the pool of immediately releasable GH vesicles, while GHRP-6 then triggers calcium-dependent exocytosis of those vesicles. Standard research combination protocols use equal micrograms of GHRP-6 and the GHRH analog in the same injection, administered simultaneously. This combination is considered the most efficient approach to maximizing GH output while keeping individual compound doses modest.
GHRP-6 is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water for injection. Standard reconstitution adds 1–2 mL of bacteriostatic water to a 5 mg vial, yielding a concentration of 2.5–5 mg/mL. Solutions should be stored at 2–8°C, protected from light, and used within 28 days. Freeze-thaw cycling should be avoided. The reconstituted solution should be clear and colorless; particulates or discoloration indicate degradation. D-amino acid content gives GHRP-6 somewhat better stability than purely L-amino acid peptides, but proper storage protocols should still be followed. Insulin syringes (29–31 gauge, 0.5–1 mL) are appropriate for subcutaneous injection.
The most consistently reported and practically significant side effect of GHRP-6 is pronounced hunger stimulation, typically beginning 15–30 minutes after injection and lasting 1–2 hours. The intensity of this hunger is notable — users frequently describe it as dramatically stronger than normal hunger, and in research contexts where caloric intake is not specifically managed, GHRP-6 predictably leads to increased food consumption. This is a direct pharmacological effect of GHS-R1a activation in hypothalamic orexigenic circuits, not an idiosyncratic reaction. For research contexts where body composition optimization is the goal, this hunger drive must be consciously managed to prevent caloric surplus from offsetting the fat-mobilizing effects of elevated GH. Pre-planning meal structure around injection timing is essential for those using GHRP-6 in body composition research.
GHRP-6 elevates cortisol and prolactin as predictable pharmacological consequences of GHS-R1a stimulation in the adrenal and pituitary lactotroph compartments. Cortisol elevation is typically 20–50% above baseline and resolves within 1–2 hours of administration. With acute use in otherwise healthy individuals, this transient cortisol increase is not expected to produce clinically significant consequences. However, with chronic multi-daily dosing over extended periods, cumulative cortisol exposure warrants attention — particularly regarding its potential effects on insulin sensitivity, bone density, and immune function. Prolactin elevation is similarly transient and typically mild, but could theoretically contribute to galactorrhea in susceptible individuals or interfere with testosterone production if prolactin rises high enough to suppress GnRH. Periodic monitoring of serum cortisol and prolactin is advisable in extended research protocols.
Like GH itself, the elevated GH levels produced by GHRP-6 stimulation can cause water and sodium retention, particularly during the initial weeks of use. Users often experience transient puffiness in the hands, feet, and face — a reflection of GH’s action on renal sodium reabsorption and interstitial fluid dynamics. More specifically, GH-induced fluid changes can increase carpal tunnel pressure, leading to numbness, tingling, or discomfort in the hands — the same carpal tunnel syndrome associated with GH replacement therapy in GH-deficient adults. These effects are typically dose-dependent and reversible upon dose reduction or discontinuation. Managing fluid retention through adequate hydration, sodium moderation, and appropriate dose titration can reduce the severity of these effects. Individuals with a history of carpal tunnel syndrome or peripheral neuropathy should use GHRP-6 with particular caution and at lower doses.
No, though they share the same receptor. Ghrelin is an endogenous 28-amino acid peptide hormone produced primarily by the stomach, where it is acylated at the serine-3 position (this acylation is required for GHS-R1a activation). GHRP-6 is a synthetic hexapeptide — structurally distinct from ghrelin — that was developed before ghrelin was even discovered. When the ghrelin receptor (GHS-R1a) was identified in 1996, researchers realized that GHRP-6 and other synthetic GHSs were activating the same receptor that ghrelin (discovered in 1999) uses. The two compounds are pharmacological siblings sharing a receptor, not the same molecule. GHRP-6’s structure is not related to ghrelin’s; it’s a coincidence of convergent pharmacology rather than structural mimicry.
GHS-R1a agonism in hypothalamic orexigenic circuits is the common mechanism, but GHRP-6 appears to have a receptor binding profile and downstream signaling character that produces stronger hypothalamic orexigenic activation than GHRP-2 or ipamorelin at comparable doses. The exact molecular basis for this differential appetite stimulation is not fully characterized but likely involves differences in receptor binding kinetics, functional selectivity (different biased signaling outcomes at the same receptor), and downstream circuit activation patterns. This is why drug development for GHS applications has focused on finding compounds that preserve GH release while minimizing appetite activation — a challenge that reflects the intrinsic coupling of GH release and orexigenic signaling through GHS-R1a.
Research data supports that GHRP-6 can substantially increase GH pulses in elderly individuals, whose age-related GH decline is primarily attributable to increased somatostatin tone and reduced GHRH pulse amplitude rather than pituitary failure. Since GHRP-6 suppresses somatostatin and directly stimulates the somatotrophs, it can partly reverse the age-related blunting of GH secretion. However, the GH peaks achieved in elderly subjects are typically smaller than in young adults, reflecting some degree of somatotroph cell reduction and receptor desensitization that accumulates with age. For true GH restoration to youthful levels, GHRP-6 combined with a GHRH analog is more effective than GHRP-6 alone. Whether restoring GH levels in elderly individuals through secretagogue use produces the same health benefits as treating true GH deficiency remains an active research question.
GHRP-6 can produce receptor desensitization with very high frequency dosing, but the typical research protocol of 2–3 administrations per day does not appear to cause meaningful long-term desensitization of GHS-R1a. The GH response to GHRP-6 is well-maintained over weeks to months in research settings using standard dosing frequencies. The scenario most associated with GHS receptor desensitization is continuous infusion or extremely high-frequency injection (more than 3–4 times daily), which produces receptor downregulation and a blunted GH response. Maintaining appropriate intervals between injections (at minimum 3–4 hours) and using sensible dosing frequencies allows sustained GH responses. Hexarelin, a more potent GHS compound, shows more pronounced desensitization than GHRP-6, which is another reason GHRP-6’s milder receptor activation profile is sometimes preferred for sustained use.
Timing is important because blood glucose and insulin levels directly modulate the GH response. Elevated insulin suppresses GH secretion through hypothalamic somatostatin activation. For maximum GH output, GHRP-6 should be injected at least 2 hours after a carbohydrate-containing meal and food should be delayed for 30 minutes after injection. A small amount of protein without fat or carbohydrate does not significantly blunt the GH response and can actually have a minor additive effect through amino acid-driven GH stimulation. In relation to exercise, GHRP-6 administered immediately before or after a training session can synergize with exercise-induced GH release, though the additional appetite stimulation on top of post-workout hunger can make caloric management challenging. Pre-sleep dosing in a fasted state is frequently cited as the most pharmacologically optimized timing.
GHRP-6 has been studied in both male and female research subjects. Women tend to have higher baseline GH secretion than men (driven by estrogen’s augmentation of GH pulsatility) and may have somewhat smaller incremental responses to GHRPs relative to their baseline. The appetite-stimulating effects are experienced equally across sexes. The prolactin-elevating effect of GHRP-6 may be of more practical relevance in women, where elevated prolactin can affect menstrual regularity and reproductive hormone balance. As with any compound affecting the GH axis, thyroid function should be monitored, as GH has interactions with thyroid hormone metabolism. Standard research dosing principles (lower starting doses, gradual titration) apply equally in women.
This is perhaps the most common conceptual question for those new to GHS research. Direct recombinant HGH (rhGH) injection delivers a bolus of exogenous growth hormone that bypasses the body’s endogenous regulation entirely. GHRP-6, by contrast, stimulates the pituitary to release its own stored GH in a pulse — maintaining the pulsatile secretion pattern and keeping the GH axis active and responsive. The pulsatile pattern matters because many of GH’s physiological effects depend on peaks and troughs rather than continuously elevated levels. Additionally, GHRP-6 preserves the normal feedback mechanisms of the GH axis (elevated GH still triggers somatostatin feedback), which prevents the GH axis suppression that can occur with exogenous rhGH. The GH produced in response to GHRP-6 is indistinguishable from endogenous GH, whereas rhGH preparations contain recombinant protein that may have subtly different pharmacokinetics and receptor binding characteristics.
The Peptide Database has detailed profiles for GHRP-6, GHRP-2, ipamorelin, hexarelin, CJC-1295, and sermorelin with side-by-side comparison of GH output, appetite effects, cortisol/prolactin profiles, and half-life data. For research protocol guidance, the AI Peptide Coach can help determine which GHS compound or combination best fits specific research goals. Dosing and reconstitution questions can be addressed with the Peptide Dosage Calculators.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.